{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-050219","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2025-05-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.823740+00:00","generated_at":"2026-05-21T02:38:24.561601+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Armata's AP-SA02 shows 100% clinical response in Phase 1b/2a S. aureus bacteremia trial","bullets":["Primary endpoints met: safety, tolerability, and clinical response in ITT (n=50).","AP-SA02 + BAT achieved 100% clinical response at TOC for BAT and EOS vs 75% for placebo (p=0.017).","No treatment-related serious adverse events; two possibly related events (liver enzyme elevation, hypersensitivity).","At day 12, responder rate 88% AP-SA02 vs 58% placebo (p=0.047); MRSA patients had no relapse.","Company plans to initiate a pivotal trial as rapidly as possible."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-050219","json":"https://secwatch.observer/filing/0001104659-25-050219.json","markdown":"https://secwatch.observer/filing/0001104659-25-050219.md","text":"https://secwatch.observer/filing/0001104659-25-050219.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000110465925050219/0001104659-25-050219-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000110465925050219/tm2515395d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T02:38:24.561601+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}